• About us
• Contact

Advertisement

Organisation › Details

Mysthera Therapeutics AG

Mysthera Therapeutics AG was founded in Basel, Switzerland by Forty51 Ventures in 2023. Pursuing a first-in-class therapeutic approach, Mysthera plans to reshape the treatment landscape for autoimmune disease. PIM kinase inhibition uniquely and selectively modulates immune cell function in multiple lineages associated with complex disease. The company's pipeline includes pre-clinical stage, PIM kinase inhibitors in-licensed from Inflection Biosciences Ltd. *

 

	Start	2023-01-01 established
	Industry	pan-PIM kinase inhibitor
	Industry 2	drug development
	Person	Cunningham, Darren (Mysthera Therapeutics 202308 CEO + Co-Founder before Inflection Biosciences + Amarin)
	Person 2	Schweighoffer, Tamás (Forty51 Advisors 202204– Partner + Co-Founder)
	Region	Basel BS
	Country	Switzerland
	Street	17 St. Jakobsstr.
	City	4052 Basel
		Address record changed: 2023-08-21
Basic data	Employees	n. a.
		* Document for »About Section«: Mysthera Therapeutics AG. (8/21/23). "Press Release: Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies". Basel.
		Record changed: 2023-08-30

Advertisement

More documents for Mysthera Therapeutics AG

• [1] Mysthera Therapeutics AG. (8/21/23). "Press Release: Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.